[18F]FDG-PET and [18F]BCPP-EF-PET will be performed on MSA patients and age-matched healthy controls to elucidate the pathophysiology of MSA.
Conditions
Interventions
None listed
Sponsors
Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For MSA patients, adults will be included without restrictions on age or sex. Healthy controls will have no sex restrictions, but their age will be limited to 40 years or older, as MSA predominantly occurs in this age group. MSA patients must meet the criteria for Clinically Established MSA or Clinically Probable MSA based on the 2022 guidelines published by the Movement Disorder Society (16). Healthy controls must be fully independent in their activities of daily living, have no history of psychiatric or neurological disorders, and have no abnormal brain MRI findings that would render them unsuitable for participation in this study, as determined by the principal investigator or co-investigators. MSA patients must not present with MRI abnormalities that would deem them unsuitable for this study, apart from the characteristic changes associated with MSA.
Exclusion criteria
Exclusion criteria: The presence of any disease, mental condition, or abnormal test findings that may interfere with participation in the study, as determined by the principal investigator. A history of hypersensitivity to [18F]BCPP-EF, [18F]FDG, or any of their components. Women for whom pregnancy cannot be ruled out based on medical history. Presence of a cardiac pacemaker. Presence of metallic implants in the body for which non-magnetic properties cannot be confirmed (e.g., cerebral aneurysm clips, mechanical heart valves, neurostimulators, insulin pumps, intraocular metal fragments, etc.). Severe communication difficulties that prevent the participant from reporting abnormalities during imaging. Poor general health condition, such as abnormal vital signs. Inability to safely discontinue medications that affect glucose metabolism or mitochondrial function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Characteristics of [18F]BCPP-EF PET and [18F]FDG PET Imaging in MSA Patients Compared to Healthy Controls | — |
Secondary
| Measure | Time frame |
|---|---|
| Association Between [18F]BCPP-EF PET and [18F]FDG PET Imaging and the Severity of Clinical Symptoms in MSA | — |
Countries
Japan
Contacts
Public ContactEtsuro Nakanishi
Kyoto University Hospital Clinical Research Consultation Desk
Outcome results
None listed